The combined assays of ctDNA and AFP yielded relatively better diagnostic performance, indicating that using ctDNA combined with conventional biomarkers may be an effective method to enhance the detection rate of HCC in the early stages. The gene discussed is AFP; the disease is hepatocellular carcinoma.